| 1 |
26264841 | Molecular dynamics and density functional studies on the metabolic selectivity of antipsychotic thioridazine by cytochrome P450 2D6: Connection with crystallographic and metabolic results. | 2015 Sep 1 |
4 |
| 2 |
23476805 | Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugs. | 2013 |
2 |
| 3 |
21976621 | Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. | 2012 Jan |
1 |
| 4 |
28520378 | Thioridazine Therapy and CYP2D6 Genotypes | 2012 |
6 |
| 5 |
23226058 | Role of cytochrome P450 genotype in the steps toward personalized drug therapy. | 2011 |
1 |
| 6 |
19482014 | Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s. | 2009 Oct 7 |
1 |
| 7 |
19604081 | Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. | 2009 Jul |
11 |
| 8 |
19902987 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. | 2009 |
1 |
| 9 |
17460606 | Factors affecting drug concentrations and QT interval during thioridazine therapy. | 2007 Nov |
1 |
| 10 |
16272405 | Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. | 2006 Mar |
1 |
| 11 |
16472104 | Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model. | 2006 Feb |
1 |
| 12 |
16805946 | Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. | 2006 Jul |
1 |
| 13 |
15572279 | Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms. | 2005 Jan |
1 |
| 14 |
15260906 | QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. | 2004 Jun |
1 |
| 15 |
12682803 | Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. | 2003 May |
9 |
| 16 |
12065442 | Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. | 2002 Jul |
1 |
| 17 |
12083975 | Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? | 2002 |
1 |
| 18 |
12503836 | QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. | 2002 Dec |
2 |
| 19 |
11802093 | Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. | 2001 Dec |
4 |
| 20 |
10855463 | Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report. | 2000 May |
1 |
| 21 |
10942178 | Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. | 2000 Aug |
4 |
| 22 |
9143866 | Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. | 1997 |
1 |
| 23 |
9352572 | Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. | 1997 Oct |
3 |
| 24 |
9435993 | Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. | 1997 Dec |
1 |
| 25 |
8653995 | Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. | 1996 Mar |
1 |
| 26 |
8946674 | Thioridazine interferences with imipramine metabolism and measurement. | 1996 Dec |
1 |